Coherus BioSciences Inc
1 day chart
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development, and commercialization of immunotherapies to treat cancer. It operates in the business of developing and commercializing the human pharmaceutical products segment. The Company’s product pipeline comprises three product candidates, toripalimab, an anti-PD-1 antibody being developed in collaboration with Junshi Biosciences; CHS-006, an antibody targeting TIGIT being developed in collaboration with Junshi Biosciences; and one wholly owned preclinical immuno-oncology program, CHS-1000, an antibody targeting ILT4. The Company markets UDENYCA (pegfilgrastim-cbqv), a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor, in the United States (the U.S). It also sells CIMERLI (ranibizumab-eqrn), a biosimilar of Lucentis, in the U.S. The Company also focused on developing Humira, a biosimilar YUSIMRY (adalimumab-aqvh) in the U.S.
Buy US stocks in Australia starting with CHRS. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in CHRS
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.